Emotionally charged FDA memos could mean fireworks at Avandia meeting
This article was originally published in Scrip
As highly charged meetings go, the two-day gathering on 5-6 June of the FDA's Endocrinologic and Metabolic Drugs (EMDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committees to review the results of a an independent readjudication of GlaxoSmithKline's controversial RECORD study of the firm's Type II diabetes drug Avandia (rosiglitazone) is expected to spark some early 4th of July fireworks, or at least, if the briefing documents are any indicator.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.